UCB SA (EBR: UCB)
Belgium
· Delayed Price · Currency is EUR | Market Cap | 30.66B |
| Revenue (ttm) | 5.45B |
| Net Income (ttm) | 240.00M |
| Shares Out | 189.72M |
| EPS (ttm) | 1.22 |
| PE Ratio | 132.26 |
| Forward PE | 27.92 |
| Dividend | 1.36 (0.84%) |
| Ex-Dividend Date | Apr 26, 2024 |
| Volume | 48,774 |
| Open | 159.60 |
| Previous Close | 161.60 |
| Day's Range | 158.80 - 163.75 |
| 52-Week Range | 65.40 - 165.75 |
| Beta | 0.36 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 27, 2025 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epi... [Read more]
Financial Performance
In 2023, UCB SA's revenue was 5.18 billion, a decrease of -4.87% compared to the previous year's 5.45 billion. Earnings were 343.00 million, a decrease of -17.94%.
Financial StatementsNews
Week In Review: UCB Sells China Drug Portfolio For $680 Million To CBC
Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies
European biopharmaceutical company UCB SA (OTC: UCBJF) (OTC: UCBJY) announced a $680 million strategic divestment deal in China. The transaction involves the sale, divestment, and license of UCB’s m...
Abu Dhabi fund Mubadala invests in UCB Pharma's China carve-out
The sovereign fund partners with Asia's healthcare investor to acquire 100% in the carve-out
Belgium's UCB to sell China neurology and allergy business for $680 mln
UCB, a Belgian biopharmaceutical firm, said on Monday that it will sell its Chinese neurology and allergy business to asset management group CBC and Abu Dhabhi's Mubadala for $680 million.
Mubadala co-invests in UCB's mature business in China to reinforce its long-term commitment to the Asian market
The transaction remains subject to certain closing conditions, including required anti-trust clearance(s) and other customary conditions, and is expected to close in Q4 2024
United Community Banks: Preferred Share Downgrade On Low Yield
United Community Banks has seen changes in business due to rising interest rates, but net interest income remains strong. Learn more about UCB stock here.